

Neuropathy Screening and Diagnosis Market - 2023-2031

<https://marketpublishers.com/r/NAB7B3B34731EN.html>

Date: February 2026

Pages: 219

Price: US\$ 2,999.00 (Single User License)

ID: NAB7B3B34731EN

Abstracts

The Neuropathy Screening and Diagnosis Market was valued at US\$ 4.2 billion in 2023 and is anticipated to reach US\$ 7.1 billion by 2031, at a CAGR of 0.067 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Neuropathy Screening and Diagnosis Market.

This report delivers a comprehensive overview of the Neuropathy Screening and Diagnosis Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Neuropathy Screening and Diagnosis Market. The Neuropathy Screening and Diagnosis Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

Neuropathy Screening and Diagnosis Market Scope:

By Disease Type

Autonomic

Diabetic Neuropathy

Peripheral Neuropathy

Focal Neuropathy

Poly Neuropathy

By Diagnosis Test

Sensory Testing

Nerve Conduction Testing

Electromyography

Autonomic Testing

Skin Biopsy

MRI Scanning

Others

By End-User

Hospitals

Neurology Clinics

Academic and Research Institutes

Others

Key Players

Eli Lilly And Company

Reddy's Laboratories

Pfizer Inc.

Cipla

Abbott Laboratories

Lupin Ltd.

NeuroBo Pharmaceuticals Inc.

NeuroMetrix Inc.

Glenmark Pharmaceuticals

Teva Pharmaceuticals

Major Highlights

This report delivers a comprehensive overview of the Neuropathy Screening and Diagnosis Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Neuropathy Screening and Diagnosis Market. The Neuropathy Screening and Diagnosis Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia)

Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Disease Type
- 3.2. Snippet by Diagnosis Test
- 3.3. Snippet by End-User
- 3.4. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Increasing Prevalence of Neuropathy
 - 4.1.1.2. Advancements In Research and Diagnostics
 - 4.1.2. Restraints
 - 4.1.2.1. High cost associated with diagnostic techniques
 - 4.1.2.2. Stringent Regulatory Compliance
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Unmet Needs
- 5.6. PESTEL Analysis
- 5.7. Patent Analysis
- 5.8. SWOT Analysis

6. BY DISEASE TYPE

6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

6.1.2. Market Attractiveness Index, By Disease Type

6.2. Autonomic *

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.3. Diabetic Neuropathy

6.4. Peripheral Neuropathy

6.5. Focal Neuropathy

6.6. Poly Neuropathy

7. BY DIAGNOSIS TEST

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test

7.1.2. Market Attractiveness Index, By Diagnosis Test

7.2. Sensory Testing*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Nerve Conduction Testing

7.4. Electromyography

7.5. Autonomic Testing

7.6. Skin Biopsy

7.7. MRI Scanning

7.8. Others

8. BY END-USER

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

8.1.2. Market Attractiveness Index, By End-User

8.2. Hospitals*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Neurology Clinics

8.4. Academic and Research Institutes

8.5. Others

9. BY REGION

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

9.1.2. Market Attractiveness Index, By Region

9.2. North America

9.2.1. Introduction

9.2.2. Key Region-Specific Dynamics

9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test

9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.2.6.1. The U.S.

9.2.6.2. Canada

9.2.6.3. Mexico

9.3. Europe

9.3.1. Introduction

9.3.2. Key Region-Specific Dynamics

9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test

9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.3.6.1. Germany

9.3.6.2. UK

9.3.6.3. France

9.3.6.4. Italy

9.3.6.5. Spain

9.3.6.6. Rest of Europe

9.4. South America

9.4.1. Introduction

9.4.2. Key Region-Specific Dynamics

9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test

9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.4.6.1. Brazil

9.4.6.2. Argentina

9.4.6.3. Rest of South America

9.5. Asia-Pacific

9.5.1. Introduction

9.5.2. Key Region-Specific Dynamics

9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test

9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.5.6.1. China

9.5.6.2. India

9.5.6.3. Japan

9.5.6.4. South Korea

9.5.6.5. Rest of Asia-Pacific

9.6. Middle East and Africa

9.6.1. Introduction

9.6.2. Key Region-Specific Dynamics

9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test

9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. COMPETITIVE LANDSCAPE

10.1. Competitive Scenario

10.2. Market Positioning/Share Analysis

10.3. Mergers and Acquisitions Analysis

11. COMPANY PROFILES

11.1. Eli Lilly And Company *

11.1.1. Company Overview

11.1.2. Product Portfolio and Description

11.1.3. Financial Overview

11.1.4. Key Developments

11.2. Reddy's Laboratories

11.3. Pfizer Inc.

11.4. Cipla

11.5. Abbott Laboratories

11.6. Lupin Ltd.

11.7. NeuroBo Pharmaceuticals Inc.

11.8. NeuroMetrix Inc.

11.9. Glenmark Pharmaceuticals

11.10. Teva Pharmaceuticals (*LIST NOT EXHAUSTIVE)

12. APPENDIX

12.1. About Us and Services

12.2. Contact Us

I would like to order

Product name: Neuropathy Screening and Diagnosis Market - 2023-2031

Product link: <https://marketpublishers.com/r/NAB7B3B34731EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NAB7B3B34731EN.html>